Brilinta ticagrelor

Dyspnea is Brilinta's single biggest adherence killer: patients routinely mistake it for a cardiac event, panic, and switch or self-discontinue, creating a high-stakes intervention window in weeks 2-6 post-initiation.

• Dyspnea dominates the patient narrative across every platform, with many patients describing the breathlessness as indistinguishable from a heart attack, fueling ER visits and abrupt switches to clopidogrel.
• The 12-month mandatory duration creates a persistent adherence cliff: patients who cannot tolerate side effects feel trapped, because they equally fear stopping due to stent thrombosis risk.
• Cost and the 2025 generic ticagrelor launch are emerging as new access stressors, with AZ removing Brilinta from its patient-assistance program in January 2026, amplifying affordability anxiety.
• Side-effect attribution confusion is widespread: patients on multi-drug regimens struggle to isolate whether dyspnea, fatigue, or joint pain belongs to Brilinta, ramipril, or their statin, delaying appropriate clinical action.